M
Myriam Henkens
Researcher at Médecins Sans Frontières
Publications - 11
Citations - 2111
Myriam Henkens is an academic researcher from Médecins Sans Frontières. The author has contributed to research in topics: Cholera & Population. The author has an hindex of 8, co-authored 11 publications receiving 1901 citations.
Papers
More filters
Journal ArticleDOI
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Dennis Falzon,Ernesto Jaramillo,Holger J. Schünemann,Matthew Arentz,Melissa Bauer,Jaime Bayona,Léopold Blanc,Jose A. Caminero,Charles L. Daley,Chris Duncombe,Christopher Fitzpatrick,Agnes Gebhard,Haileyesus Getahun,Myriam Henkens,Timothy H. Holtz,J. Keravec,S. Keshavjee,Aamir J. Khan,R. Kulier,Vaira Leimane,Christian Lienhardt,Chunling Lu,Mar'iandyshev Ao,Giovanni Battista Migliori,Fuad Mirzayev,Carole D. Mitnick,Paul Nunn,G. Nwagboniwe,Olivia Oxlade,Domingo Palmero,Patricia B Pavlinac,M. I. D. Quelapio,Mario C. Raviglione,Michael Rich,S. Royce,Sabine Rüsch-Gerdes,A. Salakaia,R. Sarin,Delphine Sculier,Francis Varaine,Marco Vitoria,Judd L. Walson,Fraser Wares,Karin Weyer,Richard A. White,Matteo Zignol +45 more
TL;DR: The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens and systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation.
Journal ArticleDOI
Substandard medicines in resource‐poor settings: a problem that can no longer be ignored
TL;DR: Governments in rich countries should not tolerate the export of substandard pharmaceutical products to poor countries, while developing country governments should improve their ability to detect substandard medicines.
Journal ArticleDOI
Genomic history of the seventh pandemic of cholera in Africa.
François-Xavier Weill,François-Xavier Weill,Daryl Domman,Elisabeth Njamkepo,Cheryl L. Tarr,Jean Rauzier,Nizar Fawal,Karen H. Keddy,Henrik Salje,Henrik Salje,Sandra Moore,Asish K. Mukhopadhyay,Raymond Bercion,Francisco J. Luquero,Antoinette Ngandjio,Mireille Dosso,Monakhova Ev,Benoit Garin,Christiane Bouchier,Carlo Pazzani,Ankur Mutreja,Ankur Mutreja,Roland Grunow,Fati Sidikou,Laurence Bonte,Sébastien Breurec,Maria Damian,Berthe Marie Njanpop-Lafourcade,Guillaume Sapriel,Anne Laure Page,Monzer Hamze,Myriam Henkens,Goutam Chowdhury,Martin A. Mengel,Jean Louis Koeck,Jean Michel Fournier,Gordon Dougan,Gordon Dougan,Patrick A. D. Grimont,Julian Parkhill,Kathryn E. Holt,Renaud Piarroux,Thandavarayan Ramamurthy,Marie Laure Quilici,Nicholas R. Thomson,Nicholas R. Thomson +45 more
TL;DR: A phylogenetic framework describes the periodicity of lineage introduction and the stable routes of cholera spread, which should inform the rational design of control measures for cholERA in Africa.
Journal ArticleDOI
Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis
Qifang Bi,Eva Ferreras,Lorenzo Pezzoli,Dominique Legros,Louise C Ivers,Louise C Ivers,Kashmira Date,Firdausi Qadri,Laura Digilio,David A. Sack,Mohammad Ali,Justin Lessler,Francisco J. Luquero,Andrew S. Azman,Andrew S. Azman,Philippe Cavailler,Nandini Sreenivasan,Helen Matzger,Francisco J. Luquero,Rebecca F. Grais,Lale Wiesner,Melissa Ko,Vanessa Rouzier,Corey M. Peak,Justine Landegger,Julia Lynch,Andrew Azman,David A. Sack,Myriam Henkens,Iza Ciglenecki,Louise C. Ivers,Emma Diggle,Mitchell Weiss,Alan R. Hinman,Kahindo Maina,Imran Mirza,Guillermo Gimeno,Myron M. Levine +37 more
TL;DR: Two kOCV doses provide protection against cholera for at least 3 years, which has important implications for outbreak management and average efficacy and direct effectiveness are estimated with random-effect models.
Journal ArticleDOI
Increasing transparency in partnerships for health--introducing the Green Light Committee.
Rajesh Gupta,Rajesh Gupta,J. Peter Cegielski,Marcos A. Espinal,Myriam Henkens,Jim Yong Kim,Catherina S. B. Lambregts-van Weezenbeek,Jong-Wook Lee,Mario C. Raviglione,Pedro G. Suarez,Francis Varaine +10 more
TL;DR: The effectiveness of the partnership emerges from its review process, flexibility to modify its modus operandi to overcome obstacles, independence from the commercial sector, and its ability to link access, rational use, technical assistance, and policy development.